International criteria for diagnosis, staging, and response to treatment in patients with neuroblastoma - PubMed (original) (raw)
International criteria for diagnosis, staging, and response to treatment in patients with neuroblastoma
G M Brodeur et al. J Clin Oncol. 1988 Dec.
Abstract
Neuroblastoma is one of the most common tumors in childhood. However, it often has been difficult to compare clinical and laboratory studies of this disease due to a lack of uniform criteria for diagnosis, staging, and response. An international group of conferees addressed each of these issues and reached a consensus. Specific criteria for making a diagnosis of neuroblastoma are defined. A new neuroblastoma staging system is proposed that takes into account the most important elements of current but incompatible systems. Finally, criteria for response to treatment are standardized. The criteria proposed herein represent an international consensus of essentially every major pediatric oncology group or organization in the United States, Europe, and Japan. The staging system should be referred to as the International Neuroblastoma Staging System, and the response criteria as the International Neuroblastoma Response Criteria. Implementation of these criteria will greatly facilitate the comparison of clinical and laboratory studies by different groups and countries. Furthermore, these criteria should serve as a foundation on which future modifications or improvements can be based.
Comment in
- The new International Neuroblastoma Staging System: some critical notes.
Carlsen NL. Carlsen NL. J Clin Oncol. 1990 May;8(5):935-6. doi: 10.1200/JCO.1990.8.5.935. J Clin Oncol. 1990. PMID: 2185343 Clinical Trial. No abstract available. - Staging of neuroblastoma.
Nagahara N, Ohkawa H, Suzuki H, Tsuchida Y, Nakajou T. Nagahara N, et al. J Clin Oncol. 1990 Jan;8(1):179. J Clin Oncol. 1990. PMID: 2295907 No abstract available.
Similar articles
- Revisions of the international criteria for neuroblastoma diagnosis, staging, and response to treatment.
Brodeur GM, Pritchard J, Berthold F, Carlsen NL, Castel V, Castelberry RP, De Bernardi B, Evans AE, Favrot M, Hedborg F, et al. Brodeur GM, et al. J Clin Oncol. 1993 Aug;11(8):1466-77. doi: 10.1200/JCO.1993.11.8.1466. J Clin Oncol. 1993. PMID: 8336186 Review. - Revisions of the international criteria for neuroblastoma diagnosis, staging and response to treatment.
Brodeur GM, Pritchard J, Berthold F, Carlsen NL, Castel V, Castelberry RP, De Bernardi B, Evans AE, Favrot M, Hedborg F, et al. Brodeur GM, et al. Prog Clin Biol Res. 1994;385:363-9. Prog Clin Biol Res. 1994. PMID: 7972232 No abstract available. - The International Neuroblastoma Risk Group (INRG) classification system: an INRG Task Force report.
Cohn SL, Pearson AD, London WB, Monclair T, Ambros PF, Brodeur GM, Faldum A, Hero B, Iehara T, Machin D, Mosseri V, Simon T, Garaventa A, Castel V, Matthay KK; INRG Task Force. Cohn SL, et al. J Clin Oncol. 2009 Jan 10;27(2):289-97. doi: 10.1200/JCO.2008.16.6785. Epub 2008 Dec 1. J Clin Oncol. 2009. PMID: 19047291 Free PMC article. - [New international staging system and classification of risk groups in neuroblastoma].
Balwierz W, Wieczorek A. Balwierz W, et al. Przegl Lek. 2010;67(6):345-9. Przegl Lek. 2010. PMID: 21344759 Polish. - Guidelines for imaging and staging of neuroblastic tumors: consensus report from the International Neuroblastoma Risk Group Project.
Brisse HJ, McCarville MB, Granata C, Krug KB, Wootton-Gorges SL, Kanegawa K, Giammarile F, Schmidt M, Shulkin BL, Matthay KK, Lewington VJ, Sarnacki S, Hero B, Kaneko M, London WB, Pearson AD, Cohn SL, Monclair T; International Neuroblastoma Risk Group Project. Brisse HJ, et al. Radiology. 2011 Oct;261(1):243-57. doi: 10.1148/radiol.11101352. Epub 2011 May 17. Radiology. 2011. PMID: 21586679
Cited by
- N-cadherin in neuroblastoma disease: expression and clinical significance.
Lammens T, Swerts K, Derycke L, De Craemer A, De Brouwer S, De Preter K, Van Roy N, Vandesompele J, Speleman F, Philippé J, Benoit Y, Beiske K, Bracke M, Laureys G. Lammens T, et al. PLoS One. 2012;7(2):e31206. doi: 10.1371/journal.pone.0031206. Epub 2012 Feb 15. PLoS One. 2012. PMID: 22355346 Free PMC article. - Loss of heterozygosity for the short arm of chromosome 1 in human neuroblastomas: correlation with N-myc amplification.
Fong CT, Dracopoli NC, White PS, Merrill PT, Griffith RC, Housman DE, Brodeur GM. Fong CT, et al. Proc Natl Acad Sci U S A. 1989 May;86(10):3753-7. doi: 10.1073/pnas.86.10.3753. Proc Natl Acad Sci U S A. 1989. PMID: 2566996 Free PMC article. - Neuroblastoma.
Shah S, Ravindranath Y. Shah S, et al. Indian J Pediatr. 1998 Sep-Oct;65(5):691-705. doi: 10.1007/BF02731044. Indian J Pediatr. 1998. PMID: 10773924 Review. - Significance of MYCN amplification in international neuroblastoma staging system stage 1 and 2 neuroblastoma: a report from the International Neuroblastoma Risk Group database.
Bagatell R, Beck-Popovic M, London WB, Zhang Y, Pearson AD, Matthay KK, Monclair T, Ambros PF, Cohn SL; International Neuroblastoma Risk Group. Bagatell R, et al. J Clin Oncol. 2009 Jan 20;27(3):365-70. doi: 10.1200/JCO.2008.17.9184. Epub 2008 Dec 1. J Clin Oncol. 2009. PMID: 19047282 Free PMC article. - What is marrow fibrosis after treatment of neuroblastoma?
Turner GE, Reid MM. Turner GE, et al. J Clin Pathol. 1993 Jan;46(1):61-3. doi: 10.1136/jcp.46.1.61. J Clin Pathol. 1993. PMID: 8432891 Free PMC article.
Publication types
MeSH terms
LinkOut - more resources
Full Text Sources
Medical